How can ‘big’ data help drug candidates through the pipeline? And who does the data belong to? LSIPR spoke to NuMedii chief executive Gini Deshpande.
R&D in the pharmaceutical industry is having a tough time. As blockbuster drugs fall foul of the so-called ‘patent cliff ’, and the cost of healthcare continues to rise, many big pharma companies, including Merck, Novartis and AstraZeneca, have resorted to laying off R&D staff to cut costs.
Pushing pipeline drugs through to the approval stage as quickly as possible is as crucial as ever, but the business of bringing new therapies to market from discovery to bathroom cabinets is an expensive and risky endeavour.
While it’s difficult to calculate the full cost of bringing a new drug to market, Forbes estimates that given the low success rate of drug candidates making it to market (95 percent of candidates fail to show their safety and efficacy, it says) on average, pharmaceutical companies will spend about $5 billion on each successful medicine.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
NuMedii, big data, drug discovery, de-risking, IP strategy
